Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020
September 07 2020 - 4:37PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that topline results from the PEDFIC 1
Phase 3 clinical trial evaluating the efficacy and safety of lead
candidate odevixibat for the treatment of progressive familial
intrahepatic cholestasis (PFIC) will be announced September 8,
2020. Company management will host a conference call and live audio
webcast at 8:30 a.m. EDT to review the results.
To access the live conference call and webcast
tomorrow, September 8, 2020, at 8:30 a.m. EDT, please
dial 877-407-0792 (domestic) or 201-689-8263 (international) and
provide the access code 13709929. The live audio webcast of the
presentation will be accessible from the Media & Investors page
of Albireo’s website, ir.albireopharma.com. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the scheduled start time. An archived
version of the webcast will be available for replay in the Events
& Presentations section of the Media & Investors page of
Albireo’s website for at least two weeks following the event.
About Albireo Albireo Pharma is a
clinical-stage biopharmaceutical company focused on the development
of novel bile acid modulators to treat orphan pediatric liver
diseases, and other liver and gastrointestinal diseases and
disorders. Albireo’s lead product candidate, odevixibat, is being
developed to treat rare pediatric cholestatic liver diseases and is
in Phase 3 development in progressive familial intrahepatic
cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial
being planned in Alagille syndrome.
Albireo was spun out from AstraZeneca in
2008. Albireo Pharma is located in Boston, Mass.,
and its key operating subsidiary is located in Gothenburg,
Sweden. The Boston Business Journal named Albireo one of
the 2020 Best Places to Work in Massachusetts for the second
consecutive year. For more information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC.,
617-430-7578
Media Contact: Colleen Alabiso, Albireo Pharma,
colleen.alabiso@albireopharma.com Claire LaCagnina, 6 Degrees,
315-765-1462, clacagnina@6degreespr.com
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024